VEON partners Mastercard to expand digital finance
VEON (NASDAQ:VEON) and Mastercard (NYSE:MA) announced a partnership aimed at expanding access to digital financial services in Ukraine, Kazakhstan, Pakistan, and Uzbekistan.
VEON (NASDAQ:VEON) and Mastercard (NYSE:MA) announced a partnership aimed at expanding access to digital financial services in Ukraine, Kazakhstan, Pakistan, and Uzbekistan.
The Ensign Group (NASDAQ:ENSG) acquired the operations of two skilled nursing facilities in Texas, expanding its healthcare portfolio in the U.S. senior care market.
France recorded 77 cases of kidnapping, unlawful detention, and extortion linked to cryptocurrency in the first half of 2026, already surpassing the approximately 45 cases documented across the whole of 2025.
Solana (CRYPTO:SOL) recorded US$147 billion in perpetual futures trading volume in the second quarter of 2026, marking a new all-time high for the network.
iQIYI (NASDAQ:IQ) announced a leadership change, appointing Ying Tian as Chief Financial Officer effective July 2, 2026.
Alphabet (NASDAQ:GOOGL) lost its final appeal after the Court of Justice of the European Union upheld a €4.1 billion fine tied to Google’s Android operating system practices.
HUTCHMED (NASDAQ:HCM) received conditional approval from China’s National Medical Products Administration for ORPATHYS® (savolitinib) to treat certain advanced gastric and gastroesophageal junction cancers.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced that the U.S. Food and Drug Administration has approved expanded use of CASGEVY (exagamglogene autotemcel) for the treatment of people ages 2 years and older with either sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.
Bitcoin (CRYPTO:BTC) Core contributor and Bitcoin Improvement Proposal maintainer Jon Atack advised users to avoid sending Bitcoin transactions during the second week of August as the network approaches the expected activation window for BIP-110.
Telix (NASDAQ:TLX) said the U.S. Food and Drug Administration agreed that safety data from Part 1 of its ProstACT Global Phase 3 trial support progression into Part 2 in the United States.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy